AMLX - Amylyx Corp Revenue Dynamics YoY (Last Twelve Months)

The Amylyx Pharmaceuticals drug portfolio is experiencing a deep crisis due to the recall of its primary medication. Cash flows have become extremely volatile, stripping the company of revenue predictability. The biotech developer focuses on ALS treatment for the global neurotherapy market. Year-over-year (TTM) sales growth from GURU.Markets illustrates revenue dynamics, where the -99.70 level indicates the state of the parameter.
amylyx.com (AMLX) - metric breakdowns and financial figures

For the long-term investor, the sustainability of Amylyx Pharmaceuticals (AMLX) is determined by its ability to scale sales of ALS therapy drugs through public and private insurance systems. This relative revenue growth over the last four quarters compared to last year measures business expansion dynamics by comparing current rolling annual figures with the same period, allowing for an assessment of the actual speed of product market penetration and the stability of cash flows.